Article

Segment 1 - Introduction to NSCLC

Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).

Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC). This includes the therapeutic importance of distinguishing NSCLC by histology. Dr Sugarbaker says that adenocarcinoma, squamous cell carcinoma (SCC), and large-cell carcinoma (LCC) are all considered in the broader category of NSCLC. The therapy for each of these histologies is determined by different indicators, and then classified into stages I-IV.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
CK Wang, MD, COTA
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo